- Home
- KAPA vs BCLI Comparison
KAPA vs BCLI Comparison
Compare KAPA & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAPA
- BCLI
- Stock Information
- Founded
- KAPA 2013
- BCLI 2000
- Country
- KAPA United States
- BCLI United States
- Employees
- KAPA N/A
- BCLI N/A
- Industry
- KAPA
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KAPA
- BCLI Health Care
- Exchange
- KAPA NYSE
- BCLI Nasdaq
- Market Cap
- KAPA 10.8M
- BCLI 9.8M
- IPO Year
- KAPA 2024
- BCLI N/A
- Fundamental
- Price
- KAPA $1.10
- BCLI $1.17
- Analyst Decision
- KAPA Strong Buy
- BCLI
- Analyst Count
- KAPA 3
- BCLI 0
- Target Price
- KAPA $8.33
- BCLI N/A
- AVG Volume (30 Days)
- KAPA 13.5M
- BCLI 395.1K
- Earning Date
- KAPA 08-23-2025
- BCLI 08-13-2025
- Dividend Yield
- KAPA N/A
- BCLI N/A
- EPS Growth
- KAPA N/A
- BCLI N/A
- EPS
- KAPA N/A
- BCLI N/A
- Revenue
- KAPA N/A
- BCLI N/A
- Revenue This Year
- KAPA N/A
- BCLI N/A
- Revenue Next Year
- KAPA N/A
- BCLI N/A
- P/E Ratio
- KAPA N/A
- BCLI N/A
- Revenue Growth
- KAPA N/A
- BCLI N/A
- 52 Week Low
- KAPA $0.40
- BCLI $0.72
- 52 Week High
- KAPA $4.00
- BCLI $6.30
- Technical
- Relative Strength Index (RSI)
- KAPA N/A
- BCLI 48.71
- Support Level
- KAPA N/A
- BCLI $1.17
- Resistance Level
- KAPA N/A
- BCLI $1.32
- Average True Range (ATR)
- KAPA 0.00
- BCLI 0.09
- MACD
- KAPA 0.00
- BCLI 0.00
- Stochastic Oscillator
- KAPA 0.00
- BCLI 50.00
About KAPA KAIROS PHARMA LTD
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.